Antibodies to β₂-Glycoprotein I Inhibit Phospholipid Dependent Coagulation Reactions

Summary

Lupus anticoagulants are antibodies that inhibit phospholipid dependent coagulation reactions in vitro. These antibodies are of clinical interest because of their association with a variety of clinical manifestations characterized by microvascular thrombosis. Although these antibodies were originally thought to be directed at negatively charged phospholipid, recent studies have suggested that they may be directed at phospholipid-protein complexes. The effect of antibodies directed against β₂-glycoprotein I (β₂-GP I, apolipoprotein H) on phospholipid-dependent coagulation reactions has been studied. Polyclonal and monoclonal antibodies to β₂-GP I were found to inhibit thrombin generation in a dose dependent manner. Inhibition of thrombin formation was due to specific interaction with β₂-GP I. There was no evidence that inhibition was due to crossreactivity with other proteins involved in the prothrombinase complex. These findings document that antibodies directed against β₂-GP I can have anticoagulant activity analogous to lupus anticoagulant activity and are consistent with the recent observation of such activity in lupus anticoagulant patient samples.

• References

• 1 McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991; 49: 193-280
• 2 Triplett DA, Brandt JT. Laboratory identification of the lupus anticoagulant. Br J Haematol 1989; 73: 139-142
• 3 Harris EN. Antiphospholipid antibodies. Br J Haematol 1990; 74: 1-9
• 4 Triplett DA. Antiphospholipid antibodies and recurrent pregnancy loss. Am J Reprod Immunol 1989; 20: 52-67
• 5 Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-698
• 6 Asherson RA, Cervera R. The antiphospholipid syndrome: a syndrome in evolution. Ann Rheum Dis 1992; 51: 147-150
• 7 Lupus Anticoagulant Working Party. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885-889
• 8 Harris EN, Boey ML, Mackworth-Young CG, Gharavi AE, Patel BM, Loizou S, Hughes GRV. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; ii: 1211-1214
• 9 Triplett DA, Brandt JT, Musgrave KA, Orr CA. The relationship between lupus anticoagulants and antibodies to phospholipid. JAMA 1988; 259: 550-554
• 10 McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid anti-bodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β₂-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990; 87: 4120-4124
• 11 Galli M, Comfurious P, Maasen C, Hemker HC, DeBaets MH, van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM. Anticardiolipin antibodies (ACA) are directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 335: 1544-1547
• 12 Laurell AB, Nilsson IM. Hypergammaglobulinemia, circulating anticoagulant and biologically false positive Wasserman reaction. J Lab Clin Med 1957; 49: 694-707
• 13 Brandt JT, Triplett DA, Musgrave K, Orr C. The sensitivity of different coagulation reagents to the presence of lupus anticoagulants. Arch Pathol Lab Med 1987; 111: 120-124
• 14 Kelsey PR, Stevenson KJ, Poller J. The diagnosis of lupus anticoagulants by the activated partial thromboplastin time – the central role of phosphatidylserine. Thromb Haemostas 1984; 52: 172-175
• 15 Thiagarajan P, Shapiro SS, DeMarco L. Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of lupus antico-agulant. J Clin Invest 1980; 66: 397-405
• 16 Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS. Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 1986; 261: 9672-9677
• 17 Rauch J, Tannenbaum M, Janoff AS. Distinguishing plasma lupus anticoagulants from anti-factor antibodies using hexagonal (II) phase phospholipids. Thromb Haemostas 1989; 62: 892-896
• 18 Rauch J, Janoff AS. Phospholipid in the hexagonal II phase is immunogenic: evidence for immunorecognition of nonbilayer lipid phases in vivo. Proc Natl. Acad Sci USA 1990; 87: 4112-4114
• 19 Edson JR, Vogt JM, Hasegawa DK. Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 1984; 64: 807-817
• 20 Fleck RA, Rapaport SA, Rao LVM. Anti-prothrombin antibodies and the lupus anticoagulant. Blood 1988; 72: 512-519
• 21 Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA. Lupus anticoagulants IgG‗s (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemostas 1991; 66: 629-632
• 22 Oosting JD, Derksen RHWM, Entjes HTI, Bouma BN, deGroot PG. Lupus anticoagulant activity is frequently dependent on the presence of β₂-glycoprotein I. Thromb Haemostas 1992; 67: 499-502
• 23 Brandt JT. Assays for phospholipid-dependent formation of thrombin and Xa: a potential method for quantifying lupus anticoagulant activity. Thromb Haemostas 1991; 66: 453-458
• 24 Brandt JT, Triplett DA. The effect of phospholipid on the detection of lupus anticoagulants by the dilute Russell Viper Venom Time. Arch Pathol Lab Med 1989; 113: 1376-1378
• 25 Exner T, Papadopoulos G, Sahman N, Koutts J. Solvent extraction of test plasmas for improved recovery of lupus anticoagulant activity. Thromb Haemostas 1990; 64: 121-123
• 26 Roubey RAS, Pratt CW, Buyon JP, Winfield JB. Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent upon β₂-glycoprotein I. J Clin Invest 1992; 90: 1100-1104
• 27 Gharavi AE, Sammaritano LR, Wen J, Elkon KB. Induction of antiphospholipid autoantibodies by immunization with β₂-glycoprotein I (apolipoprotein H). J Clin Invest 1992; 90: 1105-1109